Low-Level Laser Therapy (LLLT/PBM)Photobiomodulation: Mechanisms, Clinical Benefits, Therapeutic Evidence, Safety, and Limitations

LOW-LEVEL LASER THERAPY (LLLT/PBM)

Photobiomodulation: Mechanisms, Clinical Benefits, Therapeutic Evidence, Safety, and Limitations

A Scalar Nature Medicine Evidence-Based Medical Review

By David S. Park, DAcCHM, PhD, L.Ac., Dipl. O.M.

Founder, Scalar Nature Medicine & Scalar Do Hyun Gong

Prepared September 2026

INTRODUCTION

Low-Level Laser Therapy (LLLT), now more accurately referred to as Photobiomodulation Therapy (PBMT), is a non-invasive therapeutic approach that uses selected wavelengths of visible red and near-infrared light to influence biological activity.

Unlike high-powered surgical lasers, photobiomodulation is not intended to cut, ablate, burn, or intentionally destroy tissue.

Instead, appropriately delivered light energy interacts with biological tissue and may influence cellular signaling, mitochondrial activity, inflammation, circulation, pain regulation, and tissue-repair processes.

Within Scalar Nature Medicine, photobiomodulation is understood as a modern biophysical therapeutic modality that may be integrated with acupuncture, East Asian Medicine, rehabilitation, movement, and whole-person health care.

Its clinical effectiveness depends strongly on the actual treatment parameters.

These include:

Wavelength

Power

Irradiance

Energy density

Treatment duration

Target depth

Treatment area

Pulse characteristics

Treatment frequency

Tissue condition

Therefore, PBM is not one uniform treatment.

Two machines both called “low-level lasers” may produce substantially different biological effects.

EXECUTIVE SUMMARY

Photobiomodulation uses non-ionizing visible red or near-infrared light to influence biological activity without intentionally producing tissue destruction.

The strongest established clinical role is supportive care for prevention or treatment of oral mucositis in selected oncology settings using validated protocols.

Moderate or condition-dependent evidence supports selected applications involving:

Neck pain

Knee osteoarthritis

Tendinopathy

Plantar fasciitis

Androgenetic alopecia

Promising but less established areas include:

Chronic wounds

Diabetic foot ulcers

Chemotherapy-induced peripheral neuropathy

Research is also investigating:

Depression

Traumatic brain injury

Cognitive impairment

Dementia

Stroke

Parkinson disease

Other neurological applications

These neurological and systemic applications remain investigational.

Claims that PBM universally cures cancer, regenerates every organ, reverses all aging, or treats every disease are not supported by current clinical evidence.

EVIDENCE LEVELS

RELATIVELY STRONG EVIDENCE

Clinical Area:

Oral mucositis in selected cancer-treatment settings

Interpretation:

Protocol-specific supportive care.

PBM may reduce mucositis and treatment-related oral pain.

It is not cancer treatment.

MODERATE / CONDITION-DEPENDENT EVIDENCE

Clinical Areas:

Neck pain

Knee osteoarthritis

Tendinopathy

Plantar fasciitis

Androgenetic alopecia

Interpretation:

PBM may reduce symptoms or improve function in selected patients and is generally best used as an adjunct to comprehensive care.

PROMISING BUT LIMITED EVIDENCE

Clinical Areas:

Chronic wounds

Diabetic foot ulcers

Chemotherapy-induced peripheral neuropathy

Interpretation:

Some trials show encouraging outcomes, but studies are often small or heterogeneous.

PBM should not replace standard medical treatment.

INVESTIGATIONAL APPLICATIONS

Clinical Areas:

Depression

Traumatic brain injury

Cognition

Dementia

Stroke

Parkinson disease

Interpretation:

Research demonstrates promising signals, but evidence remains insufficient for broad routine clinical claims.

UNSUPPORTED AS A GENERAL CLAIM

Cancer cure

Universal organ regeneration

Universal rejuvenation

Treatment of all diseases

These claims are not established by clinical evidence.

1. WHAT IS PHOTOBIOMODULATION?

Photobiomodulation is the therapeutic application of non-ionizing light to produce photochemical and photophysical effects within biological tissues.

PBM may be delivered using:

Low-power lasers

Low-level lasers

Red-light devices

Near-infrared devices

Light-emitting diodes (LEDs)

The term “cold laser” is commonly used but can be misleading.

PBM is generally intended to create non-ablative and predominantly nonthermal biological effects.

However, some devices may generate noticeable warmth depending on:

Power density

Treatment duration

Distance

Contact

Device design

2. WAVELENGTHS AND TISSUE PENETRATION

Different wavelengths interact differently with biological tissues.

BLUE / VIOLET LIGHT

Approximate range:

400–500 nm

Research focus:

Superficial dermatologic applications

Selected antimicrobial applications

Superficial tissue targets

Penetration is relatively limited.

RED LIGHT

Approximate range:

600–700 nm

Common research targets:

Skin

Mucosa

Superficial wounds

Hair follicles

Shallow musculoskeletal tissues

NEAR-INFRARED LIGHT

Approximate range:

780–950 nm

Common research targets:

Muscle

Tendon

Joint

Peripheral nerve

Deeper musculoskeletal tissue

Transcranial research

LONGER INFRARED WAVELENGTHS

Above approximately 1,000 nm

Effects become highly device-dependent, and thermal interactions may become increasingly relevant.

A longer wavelength is not automatically:

Better

Stronger

Safer

More therapeutic

Clinical effectiveness depends on the entire optical dose that reaches the target tissue.

3. PROPOSED BIOLOGICAL MECHANISMS

3.1 MITOCHONDRIAL AND REDOX SIGNALING

One of the most widely discussed mechanisms involves the absorption of red or near-infrared photons by intracellular chromophores.

Cytochrome-c oxidase within mitochondria has received particular attention.

Photonic stimulation may influence:

Electron transport

Mitochondrial membrane potential

ATP availability

Reactive oxygen species signaling

Cellular transcription pathways

PBM should not simply be described as “increasing cellular energy.”

Its effects appear to be regulatory and dose-dependent rather than a universal increase in ATP or metabolism.

3.2 NITRIC OXIDE AND MICROCIRCULATION

Photobiomodulation may influence nitric oxide signaling.

Nitric oxide plays important roles in:

Vascular tone

Vasodilation

Blood-flow regulation

Cell signaling

Potential effects of PBM may include:

Transient vasodilation

Changes in microcirculation

Altered tissue oxygen availability

Improved local metabolic exchange

However, improved circulation alone does not explain all reported PBM effects.

3.3 INFLAMMATION AND IMMUNE SIGNALING

PBM may influence selected inflammatory pathways.

Experimental studies suggest possible effects involving:

Inflammatory mediators

Macrophage behavior

Oxidative stress

Edema

Cell signaling

These effects may help explain why PBM is being investigated for pain, injury, and wound-related conditions.

3.4 PAIN MODULATION

PBM may influence:

Peripheral nociceptor activity

Inflammatory signaling

Local edema

Neural activity

Tissue irritability

Clinical research suggests that appropriately dosed PBM can reduce pain in selected musculoskeletal conditions.

It should nevertheless be considered part of a broader diagnosis and rehabilitation strategy.

3.5 TISSUE REPAIR

Laboratory research has reported possible effects on:

Fibroblast activity

Collagen organization

Epithelial migration

Angiogenic signaling

Muscle recovery

Neuronal survival

These findings establish biological plausibility.

They do not automatically prove clinical effectiveness for every disease.

4. DOSIMETRY: WHY MORE IS NOT NECESSARILY BETTER

One of the most important concepts in photobiomodulation is the biphasic dose response.

Too little energy may produce little or no therapeutic effect.

An appropriate dose may stimulate beneficial biological responses.

Too much energy may reduce, reverse, or obscure the desired effect.

Therefore:

MORE POWER DOES NOT AUTOMATICALLY MEAN BETTER TREATMENT.

For reproducible PBM treatment, practitioners should document:

Wavelength

Spectral bandwidth

Output power

Irradiance in mW/cm²

Energy delivered

Radiant exposure in J/cm²

Treatment area

Beam profile

Continuous or pulsed operation

Pulse frequency

Duty cycle

Contact pressure

Angle

Distance

Tissue depth

Treatment time

Session frequency

Total treatment course

ENERGY CALCULATION

Energy = Power × Time

Energy density = Energy ÷ Treatment Area

Knowing only the total wattage of a device is not sufficient to understand the biological dose.

5. CLINICAL BENEFITS AND THERAPEUTIC EVIDENCE

5.1 ORAL MUCOSITIS ASSOCIATED WITH CANCER TREATMENT

This is among the most evidence-supported applications of photobiomodulation.

In selected patients receiving:

Radiotherapy

Chemotherapy

Hematopoietic stem-cell transplantation

protocol-based PBM may help reduce:

Incidence of severe oral mucositis

Oral pain

Ulcer duration

Difficulty eating

Treatment-related oral discomfort

MASCC/ISOO clinical guidelines support specified PBM protocols in defined oncology situations.

IMPORTANT:

PBM in this context treats a complication of cancer therapy.

It does not treat the cancer itself.

5.2 NECK PAIN

Randomized controlled trials and systematic reviews have reported short-term pain reduction and functional improvement in some people with acute or chronic neck pain.

Potential clinical roles include:

Pain reduction

Improved tolerance of movement

Improved participation in rehabilitation

Adjunctive use with therapeutic exercise

The effect remains dose- and condition-dependent.

5.3 OTHER MUSCULOSKELETAL PAIN

Research has examined PBM for:

Low-back pain

Temporomandibular pain

Fibromyalgia

Postsurgical pain

Musculoskeletal injury

Results vary according to:

Diagnosis

Dosage

Treatment location

Device

Patient population

PBM should generally complement rather than replace comprehensive rehabilitation.

5.4 KNEE OSTEOARTHRITIS

Several meta-analyses suggest PBM may improve pain and disability in selected patients with knee osteoarthritis.

Results appear more favorable when:

Appropriate treatment parameters are used

The correct anatomical tissues are targeted

PBM is combined with exercise

However, not all analyses demonstrate significant benefit.

PBM should therefore be considered an adjunct to:

Strength training

Exercise

Weight management

Patient education

Medical management when indicated

5.5 TENDINOPATHY AND PLANTAR FASCIITIS

Research examining lower-extremity tendinopathy and plantar fasciitis has reported reductions in pain and disability over short- and medium-term follow-up.

However:

Progressive loading remains a foundation of tendon rehabilitation.

PBM may help reduce symptoms sufficiently to improve participation in therapeutic exercise.

5.6 EXERCISE RECOVERY AND MUSCLE PERFORMANCE

Some research suggests PBM may help reduce:

Delayed-onset muscle soreness

Perceived fatigue

Selected markers of muscle damage

and may support recovery of muscle performance.

Results depend greatly on:

Dose

Timing

Muscle group

Training status

Treatment protocol

PBM cannot replace:

Sleep

Nutrition

Hydration

Recovery time

Appropriate training design

5.7 WOUND HEALING

PBM has been investigated as an adjunctive therapy for wound healing.

Experimental and clinical research suggests potential effects involving:

Fibroblast activity

Collagen organization

Epithelial migration

Microcirculation

Inflammatory regulation

Tissue repair signaling

Clinical protocols vary substantially, however, and treatment should be individualized.

5.8 DIABETIC FOOT ULCERS

Some randomized trials and meta-analyses suggest that PBM added to standard wound care may improve:

Wound-area reduction

Healing probability

Selected wound-healing measurements

However, PBM must never replace:

Vascular assessment

Infection management

Debridement when needed

Pressure offloading

Glucose management

Appropriate dressings

Medical supervision

5.9 ANDROGENETIC ALOPECIA

Red-light and low-level-light therapies have been studied for male and female pattern hair loss.

Sham-controlled studies and meta-analyses suggest repeated PBM treatment can increase hair:

Count

Density

in some patients.

Treatment usually requires repeated exposure over months.

PBM is more biologically plausible where viable but miniaturized hair follicles remain.

It cannot regenerate hair follicles that no longer exist.

6. SKIN CARE AND COSMETIC APPLICATIONS

Photobiomodulation is increasingly incorporated into cosmetic and skin-care programs.

Potential areas of interest include:

Skin recovery

Support of tissue repair

Red-light facial treatment

Inflammation modulation

Hair-loss management

Post-procedure recovery

However, cosmetic claims require careful interpretation.

The strongest evidence reviewed in this report relates more directly to:

Androgenetic alopecia

Selected wound-healing applications

General claims that PBM:

Reverses biological age

Regenerates all facial tissues

Eliminates all wrinkles

Produces guaranteed rejuvenation

are not established by current evidence.

Within Scalar Nature Medicine, cosmetic PBM should therefore be positioned as a supportive biophysical rejuvenation modality rather than a miracle anti-aging treatment.

7. CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Small randomized and phase-II studies have investigated PBM for symptoms associated with chemotherapy-induced peripheral neuropathy.

Reported potential benefits include reductions in:

Numbness

Pain

Sensory disturbance

Functional impairment

The evidence remains developing.

PBM for these patients should be coordinated with the oncology team.

8. NEUROLOGICAL AND NEUROPSYCHIATRIC RESEARCH

Transcranial photobiomodulation is one of the most interesting emerging areas of PBM research.

Conditions under investigation include:

Depression

Persistent symptoms after traumatic brain injury

Cognitive impairment

Dementia

Stroke

Parkinson disease

Small studies and early meta-analyses have reported promising signals involving:

Mood

Attention

Memory

Sleep

Post-concussion symptoms

Cognition

However, significant limitations remain.

These include:

Small sample sizes

Different devices

Different wavelengths

Different treatment protocols

Variable skull penetration

Short follow-up periods

Possible publication bias

Therefore:

TRANSCRANIAL PBM REMAINS INVESTIGATIONAL FOR MANY NEUROLOGICAL CONDITIONS.

It should not replace established neurological or psychiatric care.

9. REPRESENTATIVE CLINICAL SUCCESSES

ONCOLOGY ORAL MUCOSITIS

Clinical signal:

Reduced severe mucositis and oral pain in selected protocols.

Interpretation:

Among the strongest clinical applications of PBM, but it is supportive oncology care rather than cancer treatment.

NECK PAIN

Clinical signal:

Pain reduction compared with sham treatment in pooled clinical trials.

Interpretation:

Generally short-term and dependent on the treatment protocol.

LOWER-EXTREMITY TENDINOPATHY

Clinical signal:

Improvement in pain and disability.

Interpretation:

Best integrated with progressive loading and rehabilitation.

PATTERN HAIR LOSS

Clinical signal:

Improved hair density or hair count following repeated treatment.

Interpretation:

Treatment is gradual and does not restore follicles that are permanently absent.

DIABETIC FOOT ULCERS

Clinical signal:

Improved healing measurements when PBM is added to standard wound care.

Interpretation:

Never a substitute for infection control, vascular care, metabolic management, and pressure reduction.

TRAUMATIC BRAIN INJURY / COGNITION

Clinical signal:

Improvements reported in selected small sham-controlled studies.

Interpretation:

Promising but not yet an established routine treatment.

CLINICAL SUCCESS MUST BE INTERPRETED RESPONSIBLY

Individual before-and-after photographs and testimonials can be useful observations.

However, they do not establish proof.

The most scientifically reliable clinical success is demonstrated through:

Randomized trials

Sham controls

Blinding

Prespecified outcomes

Clearly reported treatment parameters

Replication

Clinically meaningful follow-up

10. SAFETY

PBM is generally well tolerated when appropriate equipment and validated protocols are used.

Reported adverse effects are usually mild and temporary.

Possible reactions include:

Redness

Warmth

Tingling

Temporary symptom fluctuation

Headache

Fatigue

11. EYE SAFETY

The most important preventable hazard is inappropriate ocular exposure.

This is particularly important because near-infrared light may be invisible.

Essential precautions include:

Use wavelength-appropriate protective eyewear.

Follow the laser classification and safety instructions of the device.

Never intentionally direct the beam into the eye.

Avoid treatment directly over the eyelid unless the specific device and protocol are designed and authorized for that use.

Protect the practitioner as well as the patient when required.

12. ADDITIONAL PRECAUTIONS

Inspect:

Skin

Sensation

Applicator

Cables

Device condition

before treatment.

Exercise caution with:

Photosensitivity disorders

Photosensitizing medications

Avoid unverified treatment over a known or suspected tumor unless part of an oncology-approved treatment protocol.

Pregnancy safety has not been fully established.

Indiscriminate treatment over the pregnant uterus should be avoided.

Unexplained:

Lesions

Infection

Ischemia

Progressive neurological deficits

Suspected malignancy

require appropriate medical evaluation.

13. CANCER: A CRITICAL DISTINCTION

Photobiomodulation should never be described as a universal cancer cure.

Its strongest oncology role is currently the management of certain treatment-related adverse effects, especially oral mucositis.

Treatment close to active tumors requires individualized risk-benefit evaluation and coordination with the oncology team.

Evidence showing that PBM reduces treatment-related toxicity cannot be extrapolated to claim that PBM:

Kills cancer

Eliminates tumors

Prevents cancer recurrence

Cures malignancy

14. LASER VERSUS LED

LOW-LEVEL LASER

Optical characteristics:

Narrower beam

Higher directionality

Usually coherent at the source

Potential clinical advantage:

Precise treatment of smaller targets

Important limitation:

Coherence alone does not guarantee greater therapeutic effectiveness.

Safety:

Direct or reflected eye exposure may be hazardous.

LED-BASED PBM

Optical characteristics:

Broader illumination

More divergent light

Noncoherent output

Potential clinical advantage:

Useful for larger treatment fields.

LED devices can produce biologically meaningful PBM when wavelength and dose are appropriate.

High-intensity LED systems also require appropriate eye-safety assessment.

THE IMPORTANT QUESTION

The most clinically important question is not simply:

“Is it laser or LED?”

The important question is:

Does the correct optical dose reach the intended biological target safely and reproducibly?

15. INTEGRATION WITH SCALAR NATURE MEDICINE

Within Scalar Nature Medicine, photobiomodulation can be classified as a modern biophysical therapeutic modality.

It may be integrated with:

Acupuncture

East Asian Medicine

Manual therapy

Tuina

Movement rehabilitation

Therapeutic exercise

Scalar Do Hyun Gong

Lifestyle medicine

Conventional medical treatment

The purpose is not to claim that light cures every disorder.

The purpose is to use an appropriate physical stimulus to support a clearly defined therapeutic objective.

16. PBM AND ACUPUNCTURE

Photobiomodulation may be incorporated into acupuncture-oriented practice in several ways.

Potential applications include:

Non-invasive stimulation of painful locations

Treatment of selected acupuncture points

Support of local tissue recovery

Pain reduction before therapeutic exercise

Alternative stimulation where needle insertion is undesirable

When the term “laser acupuncture” is used, an important scientific distinction should be maintained.

Effects caused by local photobiomodulation should not automatically be attributed uniquely to acupuncture-point selection.

Both mechanisms may be investigated, but they should not be confused.

17. PBM AND REHABILITATION

PBM may be particularly useful when integrated with rehabilitation.

A practical conceptual sequence is:

ASSESS

PBM

PAIN REDUCTION / TISSUE SUPPORT

MOVEMENT

THERAPEUTIC EXERCISE

STRENGTHENING

FUNCTIONAL RESTORATION

In this model:

PBM does not replace rehabilitation.

PBM may help create a physiological environment in which rehabilitation becomes easier or more tolerable.

18. PBM AND SCALAR DO HYUN GONG

Scalar Do Hyun Gong emphasizes:

Movement

Breathing

Relaxation

Balance

Body awareness

Coordination

Functional cultivation

PBM may complement movement practice when clinically appropriate by supporting selected goals involving:

Pain

Muscular recovery

Tendon symptoms

Joint discomfort

Tissue recovery

However:

The machine provides a biological stimulus.

Movement restores function.

19. THE SCALAR NATURE MEDICINE INTEGRATION PRINCIPLE

The Scalar Nature Medicine approach can be expressed as:

LIGHT

+

MOVEMENT

+

ACUPUNCTURE

+

NATURAL MEDICINE

+

REHABILITATION

+

NUTRITION

+

SLEEP

+

STRESS REGULATION

+

LIFE CULTIVATION

=

WHOLE-PERSON HEALTH SUPPORT

No single modality should be expected to perform the entire healing process.

20. CLINICAL DOCUMENTATION

For reproducible clinical practice, document:

Treatment indication

Anatomical target

Acupuncture point if applicable

Wavelength

Power

Spot size

Irradiance

Energy delivered

Energy density

Contact method

Treatment time

Session frequency

Concurrent therapies

Clinical response

Adverse events

21. CLINICAL GOVERNANCE

A responsible PBM program should incorporate:

Indication-specific protocols

Appropriately maintained equipment

Operator training

Eye-safety procedures

Informed consent

Patient screening

Objective outcome measurement

Adverse-event documentation

Clinical follow-up

22. OUTCOME MEASUREMENT

Depending on the condition, useful outcomes may include:

Pain scales

Disability scales

Range of motion

Functional testing

Wound area

Standardized photographs

Hair count

Hair density

Medication use

Strength

Patient-reported function

Adverse events

Duration of benefit

23. IMMEDIATE IMPROVEMENT DOES NOT ALWAYS MEAN TISSUE REPAIR

Patients may sometimes report an immediate improvement after treatment.

This can be clinically meaningful.

However, immediate change should not automatically be interpreted as proof of structural healing.

Possible contributors include:

Pain modulation

Sensory effects

Placebo response

Natural symptom fluctuation

Measurement variability

Concurrent treatments

Longer-term improvement should be assessed through appropriate follow-up.

24. PHOTOBIOMODULATION AND REJUVENATION

Within Scalar Nature Medicine, rejuvenation is broader than cosmetic appearance.

Rejuvenation includes:

Functional capacity

Movement

Strength

Circulation

Tissue health

Recovery

Sleep

Mental vitality

Resilience

PBM may support selected components of this process.

However:

Photobiomodulation has not been scientifically established as a universal method for reversing biological aging.

It should therefore be presented as one potential component of a comprehensive rejuvenation strategy.

25. PHOTOBIOMODULATION AND “ENERGY MEDICINE”

Photobiomodulation provides an important example of the need for precision when discussing energy.

The light used in PBM is measurable physical electromagnetic energy.

Its parameters can be quantified.

These include:

Wavelength

Power

Irradiance

Energy

Treatment area

Treatment time

This should be distinguished from broader metaphysical or biofield concepts explored within Scalar Nature Medicine.

Biomedical mechanisms of PBM should first be explained using established photobiology and physiology.

That scientific clarity strengthens integrative medicine.

26. THE DOSE IS THE MEDICINE

The central PBM principle can be summarized as:

TOO LITTLE

=

Possibly ineffective

APPROPRIATE DOSE

=

Potential therapeutic biological response

TOO MUCH

=

Potentially reduced effect or unwanted biological response

Therefore:

PRECISION IS MORE IMPORTANT THAN POWER.

27. WHAT PBM DOES NOT PROVE

Current evidence does not establish that PBM universally:

Cures cancer

Treats all diseases

Regenerates every organ

Reverses biological aging

Eliminates all inflammation

Restores every damaged nerve

Replaces conventional medicine

Making these distinctions does not weaken photobiomodulation.

It strengthens its credibility.

28. WHAT PBM CAN REASONABLY OFFER

Depending on the condition and protocol, PBM may provide useful adjunctive support for:

Selected musculoskeletal pain

Neck pain

Selected osteoarthritis symptoms

Tendinopathy

Plantar fasciitis

Oral mucositis associated with cancer treatment

Selected wound-care applications

Androgenetic alopecia

Exercise recovery

Selected investigational neurological applications

The evidence differs considerably among these conditions.

29. FINAL MEDICAL ASSESSMENT

Photobiomodulation is a legitimate and biologically plausible therapeutic modality with meaningful clinical evidence in selected indications.

Its most defensible clinical roles currently include:

Protocol-specific supportive treatment for oral mucositis

and

Adjunctive management of selected musculoskeletal pain conditions.

Evidence is encouraging but less definitive for:

Chronic wounds

Diabetic foot ulcers

Androgenetic alopecia

Chemotherapy-induced peripheral neuropathy

Neurological, neurodegenerative, systemic anti-aging, organ-regeneration, and universal disease-curing applications remain investigational or unsupported.

The therapeutic result depends on:

Wavelength

Tissue penetration

Irradiance

Radiant exposure

Treatment geometry

Timing

Biological context

PBM should therefore be practiced as a precisely measured optical intervention rather than generic “healing light.”

30. SCALAR NATURE MEDICINE CLINICAL INTERPRETATION

Within Scalar Nature Medicine, photobiomodulation is best positioned as a measured light-based adjunct that may support selected therapeutic goals involving:

Pain management

Tissue recovery

Rehabilitation

Wound care

Hair-loss management

Selected supportive oncology care

Rejuvenation-oriented skin and tissue programs

Its greatest clinical value comes from combining precise photobiological stimulation with:

Accurate diagnosis

Appropriate patient selection

Acupuncture when indicated

Movement

Rehabilitation

Exercise

Nutrition

Sleep

Stress regulation

Whole-person health care

THE CENTRAL PRINCIPLE

Photobiomodulation demonstrates a fundamental Scalar Nature Medicine concept:

PHYSICAL ENERGY

BIOLOGICAL SIGNAL

CELLULAR RESPONSE

TISSUE RESPONSE

ADAPTATION

FUNCTION

The light initiates the signal.

The living body performs the biological response.

CONCLUSION

Low-Level Laser Therapy, or Photobiomodulation Therapy, represents an important modern bridge between physics and biology.

Red and near-infrared light can influence cellular and tissue processes without intentionally destroying tissue.

Clinical evidence demonstrates meaningful potential in selected applications, particularly:

Oral mucositis

Musculoskeletal pain

Knee osteoarthritis

Tendinopathy

Plantar fasciitis

Pattern hair loss

Selected wound-care situations

Research continues in many other areas.

Within Scalar Nature Medicine, PBM can be integrated with acupuncture, movement, rehabilitation, natural medicine, and whole-person health care.

The most important principle is not simply:

“Use light.”

It is:

CHOOSE THE CORRECT WAVELENGTH.

DELIVER THE CORRECT DOSE.

TARGET THE CORRECT TISSUE.

MEASURE THE RESPONSE.

INTEGRATE THE TREATMENT.

And always remember:

THE DEVICE PROVIDES THE STIMULUS.

THE BODY PERFORMS THE HEALING AND REMODELING.

MEDICAL & SCIENTIFIC DISCLAIMER

This publication is intended for professional education and general health information.

It does not diagnose, prescribe, or replace individualized medical care.

Photobiomodulation parameters, indications, contraindications, and regulatory status vary according to device and clinical context.

Clinical use should follow:

Applicable scope-of-practice requirements

Manufacturer instructions

Laser and eye-safety procedures

Appropriate patient screening

Informed consent

Evidence-based clinical protocols

Serious, progressive, unexplained, oncological, vascular, neurological, infectious, or wound-related conditions require appropriate medical evaluation and referral.

Photobiomodulation should not be considered a universal cure or a replacement for necessary medical treatment.

ABOUT THE AUTHOR

David S. Park, DAcCHM, PhD, L.Ac., Dipl. O.M.

Founder of Scalar Nature Medicine and Scalar Do Hyun Gong.

His work integrates East Asian Medicine, acupuncture, natural medicine, movement, Qigong, meditation, rejuvenation, healthy aging, mind-body cultivation, biophysical therapeutic methods, and whole-person approaches to health and human development.

SELECTED REFERENCES

1. Zadik Y, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients. Support Care Cancer. 2019.

2. Elad S, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020.

3. Cruz AR, et al. Efficacy of photobiomodulation in the treatment of oral mucositis: systematic review and meta-analysis. 2023.

4. Shen B, et al. Photobiomodulation in oral mucositis among patients with head and neck cancer: systematic review and meta-analysis. 2024.

5. Chow RT, et al. Efficacy of low-level laser therapy in the management of neck pain: systematic review and meta-analysis. Lancet. 2009.

6. Gross AR, et al. Low-level laser therapy for neck pain. Cochrane Database Syst Rev. 2013.

7. Skelly AC, et al. Noninvasive nonpharmacological treatment for chronic pain: systematic review update. 2020.

8. de Oliveira MF, et al. Low-intensity laser and LED photobiomodulation for musculoskeletal pain. 2022.

9. Stausholm MB, et al. Efficacy of LLLT on pain and disability in knee osteoarthritis. BMJ Open. 2019.

10. Rayegani SM, et al. Safety and effectiveness of LLLT in knee osteoarthritis: systematic review and meta-analysis. 2017.

11. Huang Z, et al. Effectiveness of LLLT in knee osteoarthritis: systematic review and meta-analysis. Osteoarthritis Cartilage. 2015.

12. Naterstad IF, et al. LLLT in lower-extremity tendinopathy and plantar fasciitis: systematic review and meta-analysis. BMJ Open. 2022.

13. Li S, et al. LLLT for healing diabetic foot ulcers: systematic review and meta-analysis. 2020.

14. Santos NR, et al. PBM parameters in resolution of diabetic foot ulcers: systematic review and meta-analysis. 2021.

15. Tchanque-Fossuo CN, et al. LLLT for diabetic foot ulcers: systematic review and meta-analysis. 2018.

16. Adil A, Godwin M. Effectiveness of treatments for androgenetic alopecia: systematic review and meta-analysis. J Am Acad Dermatol. 2017.

17. Liu KH, et al. Meta-analysis of PBM for androgenetic alopecia. 2019.

18. Suchonwanit P, et al. Efficacy and safety of LLLT for androgenetic alopecia: randomized sham-controlled trial. 2018.

19. Updated network meta-analysis of monotherapies for male androgenetic alopecia. 2024.

20. Argenta PA, et al. PBM for chemotherapy-induced peripheral neuropathy: randomized sham-controlled trial. 2017.

21. Teng C, et al. PBM for chemotherapy-induced peripheral neuropathy: randomized phase II trial. 2023.

22. NEUROLASER trial: PBM prevention of chemotherapy-induced peripheral neuropathy. 2022.

23. Systematic reviews of noninvasive neuromodulation for chemotherapy-induced peripheral neuropathy. 2018–2024.

24. Ji E, et al. PBM for depression: systematic review and meta-analysis of randomized trials. 2024.

25. Lee TL, et al. Transcranial PBM and cognitive outcomes: systematic review. 2023.

26. Zeng J, et al. Transcranial PBM for cognitive outcomes after traumatic brain injury. 2024.

27. Montazeri K, et al. Transcranial PBM in common brain disorders: systematic review. 2021.

28. Salehpour F, et al. Transcranial PBM and cognitive performance: systematic review and meta-analysis. 2019.

29. Lee TL, et al. Sham-controlled transcranial PBM study in traumatic brain injury. 2025.

30. U.S. Food and Drug Administration. Photobiomodulation (PBM) Devices: Premarket Notification [510(k)] Submissions—Draft Guidance.

31. U.S. Food and Drug Administration. Frequently Asked Questions About Lasers.

32. U.S. Food and Drug Administration. Laser Products and Instruments.

33. U.S. Food and Drug Administration. Low Level Laser System for Aesthetic Use—Class II Special Controls Guidance.

34. Robijns J, et al. Photobiomodulation therapy in management of cancer therapy side effects: position paper. 2022.

Previous
Previous

Sciatica

Next
Next

HIFU and Ultrasound Cavitation: From Skin Rejuvenation and Body Contouring to Modern Focused-Ultrasound Medicine